Compare FRBA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBA | IPSC |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 362.5M |
| IPO Year | N/A | 2021 |
| Metric | FRBA | IPSC |
|---|---|---|
| Price | $19.02 | $1.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.50 | $4.25 |
| AVG Volume (30 Days) | 94.5K | ★ 659.7K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $6.08 | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $14.41 | $0.44 |
| 52 Week High | $19.18 | $2.97 |
| Indicator | FRBA | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 40.80 |
| Support Level | $16.84 | $1.90 |
| Resistance Level | $19.09 | $2.62 |
| Average True Range (ATR) | 0.42 | 0.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 81.48 | 13.85 |
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.